Diabetes screening tests are becoming more commonly used in India. This large-scale screening for diabetes has been predicted to be ineffective, as per current available survey conducted by Sanjay Basu of Stanford University and colleagues. The predictions of this simulation suggest that large numbers of false positive results would waste financial resources, and that focusing on symptom-based screening and on improvements to diabetes treatment might better serve India's population.
Researchers developed a microsimulation model (a computer model that operates at the level of individuals) to investigate the implications of using alternative screening instruments for identifying people with undetected diabetes across India. Depending on the screening approach, between 158 million and 306 million of the 567 million Indians eligible for screening would be referred for confirmatory testing. However, it was seen that between 126 million and 273 million of these high-risk individuals would be false positives; only between 26 million and 37 million would meet the international diagnostic criteria for diabetes.
The researchers estimate that the cost per case found would vary from $5.28 (for random glucose screening) to $17.06 (for a survey-based screening instrument). Finally, they estimate that the total cost for screening the eligible population would be between 169-567 million dollars.
The study appears in PLOS Medicine.